Researchers have identified a “master regulator” gene, ZNFX1, that may act as a biomarker to help guide treatment in future clinical trials involving patients with therapy-resistant ovarian cancer, according to a study recently published in Cancer Research.
Elana J. Fertig was named associate director for quantitative science at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
